Patents by Inventor Ji Youn MIN

Ji Youn MIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NLRP3 PROTEIN DEGRADATION INDUCING COMPOUND
    Publication number: 20250073218
    Abstract: The present invention relates to NLRP3 protein degradation inducing compounds. Specifically, the present invention provides a bifunctional compound in which an NLRP3 protein binding moiety and an E3 ubiquitin ligase binding moiety are connected by a chemical linker, a method for preparing the same, a method for degrading NLRP3 protein using the same, and the use for preventing or treating NLRP3 inflammasome-related diseases.
    Type: Application
    Filed: November 4, 2021
    Publication date: March 6, 2025
    Applicant: UPPTHERA
    Inventors: Soo Hee Ryu, Ji Hoon Ryu, Hwa Jin Lee, Im Suk Min, Han Kyu Lee, Jun Kyu Lee, Ji Su Lee, Su Youn Koh, Seong Hoon Kim
  • Pharmaceutical composition for treatment of cancer comprising RNA oligonucleotide
    Patent number: 10337016
    Abstract: The present disclosure provides a pharmaceutical composition for treating cancer comprising an RNA oligonucleotide having a particular sequence and structure. Specifically, when a cell line is treated with an RNA oligonucleotide having specific sequence and helical bend structure according to the present disclosure, the expression of ISG56 is increased and apoptosis of cancer cells is induced. Thus, a composition comprising the RNA oligonucleotide can be used as an anticancer agent.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: July 2, 2019
    Assignee: KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Byong-Seok Choi, Suk-Jo Kang, Janghyun Lee, Ji Youn Min, Dongmin Chun, Si-Eun Sung
  • PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER COMPRISING RNA OLIGONUCLEOTIDE
    Publication number: 20170306330
    Abstract: The present disclosure provides a pharmaceutical composition for treating cancer comprising an RNA oligonucleotide having a particular sequence and structure. Specifically, when a cell line is treated with an RNA oligonucleotide having specific sequence and helical bend structure according to the present disclosure, the expression of ISG56 is increased and apoptosis of cancer cells is induced. Thus, a composition comprising the RNA oligonucleotide can be used as an anticancer agent.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 26, 2017
    Inventors: Byong-Seok CHOI, Suk-Jo KANG, Janghyun LEE, Ji Youn MIN